Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
Mohamed ElmeliegyJason Den HaeseChetasi TalatiMeir WetzlerWilliam J JuskoPublished in: Cancer chemotherapy and pharmacology (2020)
Simultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AML patients with FLT3 mutations.